SC
TSHA icon

Stempoint Capital’s Taysha Gene Therapies TSHA Stock Holding History

Stempoint Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-182,130
Closed -$1M – 115
2025
Q4 		$1M Sell
182,130
-657,539
-78% -$3.19M 0.17% 69
2025
Q3 		$2.75M Sell
839,669
-364,272
-30% -$1.03M 0.55% 43
2025
Q2 		$2.78M Buy
+1,203,941
New +$2.62M 0.89% 33
2024
Q2 		– Sell
-1,087,785
Closed -$3.12M – 73
2024
Q1 		$3.12M Buy
+1,087,785
New +$2.27M 0.83% 33

Other funds holding TSHA

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stempoint Capital's TSHA Position: Q1 2026 in Review

Stempoint Capital sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 182,130 shares — an estimated $1M sold.

Stempoint Capital first reported a position in TSHA in Q1 2024 and held it in 4 quarters. The position peaked at $3.12M in Q1 2024. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Stempoint Capital reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 182,130 Taysha Gene Therapies shares in Q1 2026, an estimated $1M.
  • Stempoint Capital first reported a position in Taysha Gene Therapies in Q1 2024 and held it in 4 quarters.
  • Stempoint Capital's Taysha Gene Therapies position peaked at $3.12M in Q1 2024.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.